AstraZeneca PLC believes an emerging highly sensitive test for levels of troponin – proteins associated with heart damage – could help identify those who get the most benefit from treatment with its Brilinta, potentially improving the drug’s value proposition against generic clopidogrel.
FDA-approved since July 2011 for reducing the rate of thrombotic cardiovascular events in patients with acute coronary syndromes, the novel...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?